Vascular inflammation is a risk factor associated with brain atrophy and disease severity in Parkinson's disease: A case-control study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
Introduction . Systemic inflammation with elevated oxidative stress causing neuroinflammation is considered a major factor in the pathogenesis of Parkinson’s disease (PD). The interface between systemic circulation and the brain parenchyma is the blood-brain barrier (BBB), which also plays a role in maintaining neurovascular homeostasis. Vascular cell adhesion molecule-1 (VCAM-1) and microRNAs (miRNAs) regulate brain vessel endothelial function, neoangiogenesis, and, in turn, neuronal homeostasis regulation, such that their dysregulation can result in neurodegeneration, such as gray matter atrophy, in PD. Objective . Our aim was to evaluate the associations among specific levels of gray matter atrophy, peripheral vascular adhesion molecules, miRNAs, and clinical disease severity in order to achieve a clearer understanding of PD pathogenesis. Methods . Blood samples were collected from 33 patients with PD and 27 healthy volunteers, and the levels of VCAM-1 and several miRNAs in those samples were measured. Voxel-based morphometry (VBM) analysis was performed using 3 T magnetic resonance imaging (MRI) and SPM (Statistical Parametric Mapping software program). The associations among the vascular parameter, miRNAs, gray matter volume, and clinical disease severity measurements were evaluated by partial correlation analysis. Results . The levels of VCAM-1, miRNA-22, and miRNA-29a expression were significantly elevated in the PD patients. The gray matter volume atrophy in the left parahippocampus, bilateral posterior cingulate gyrus, fusiform gyrus, left temporal gyrus, and cerebellum was significantly correlated with increased clinical disease severity, the upregulation of miRNA levels, and increased vascular inflammation. Conclusion . Patients with PD seem to have abnormal levels of vascular inflammatory markers and miRNAs in the peripheral circulation, and these levels are correlated with specific brain volume changes. This study reinforces the associations among peripheral inflammation, the BBB interface, and gray matter atrophy in PD and further demonstrates that BBB dysfunction with neurovascular impairment may play an important role in PD progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Vascular factors of Parkinson disease, modified by two hit vascular model references [6]. Peripheral inflammation with vascular factor-like hypertension, diabetes, aging process, and genetic factors for PD, leading to neurovascular unit (NUV) impairment (panel A) and BBB dysfunction (panel B). In panel A, abnormal neurovascular alterations cause changes in vascular perfusion in the cerebral blood flow and oxygen consumption and cerebral flow hypoperfusion with small vessel atherosclerosis, further leading to neoangiogenesis and neuroinflammation. In panel B, peripheral inflammation and the aging process can cause BBB dysfunction, with inflammatory factors infiltrating into the neurons and adjacent supporting tissue. Inflammation also causes neurotoxin accumulation in brain tissues and vascular damage that changes microvessel integrity, leading to microvascular hypoperfusion (oligaemia) and inducing neoangiogenesis, which in turn result in macrobrain structural changes like white matter hypertrophy and gray mater atrophy, which are in turn correlated with clinical disease progression. Abbreviations: VCAM-1: vascular cell adhesion molecule-1; UPDRS: Unified Parkinson's Disease Rating Scale; VBM: voxel-based morphology.](https://figures.cochat.ai/paper-figures/23f4db926d2a48c499f60a622840cb00/vascular-inflammation-is-a-risk-factor-associated-with-brain-atrophy-and-disease-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Parkinson’s disease (PD) has been characterized as a progressive neurological disorder without any available cure or preventative treatment [1, 2].”
BackgroundHughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
A fast diffeomorphic image registration algorithm
Ashburner, J. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.07.007 · Cited by 8,122
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437 · cited 1×
“Under conditions of inflammation, the microglial release of proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin- (IL-) 1β, and transforming growth factor-β, acts on the endothelium of BBB cells to stimulate the upregulation of VCAM-1 and ICAM-1, causing the transmigration of leukocyte…”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“Neurovascular status changes in the brain due to BBB dysfunction and aberrant angiogenesis cause white matter lesions (leukoaraiosis) [7], vessel regression, and brain hypoperfusion [21].”
BackgroundBlood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Goetz, C. G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G. T., Counsell, C., Giladi, N., Holloway, R. G., Moore, C. G., Wenning, G. K., et al. (2004) · Movement Disorders · doi:10.1002/mds.20213 · Cited by 2,347
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity
Van Den Eeden, S. K. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,747
Hughes, A. J., Ben-Shlomo, Y., Daniel, S. E., & Lees, A. J. (1992) · Neurology · doi:10.1212/wnl.42.6.1142 · Cited by 1,313 · cited 1×
“Thirtythree patients (11 males and 22 females; mean age 63:1 ± 9:09 years) with idiopathic PD diagnosed according to the United Kingdom Brain Bank criteria [22] by an experienced neurology specialist and without a history of other neurologic or psychiatric illness or psychotropic medication use were prospectively enro…”
MethodBrysbaert, M. (2019) · Journal of Cognition · doi:10.5334/joc.72 · Cited by 996
The role of the parahippocampal cortex in cognition
Aminoff, E. M., Kveraga, K., & Bar, M. (2013) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2013.06.009 · Cited by 855
The functional architecture of the ventral temporal cortex and its role in categorization
Grill-Spector, K., & Weiner, K. S. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3747 · Cited by 837
Gender differences in Parkinson's disease
Haaxma, C. A., Bloem, B. R., Borm, G. F., Oyen, W. J. G., Leenders, K. L., Eshuis, S., Booij, J., Dluzen, D. E., & Horstink, M. W. I. M. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.103788 · Cited by 741
The cerebellum: adaptive prediction for movement and cognition
Sokolov, A. A., Miall, R. C., & Ivry, R. B. (2017) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2017.02.005 · Cited by 691
Inflammation as a causative factor in the aetiology of Parkinson's disease
Whitton, P. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707167 · Cited by 624
Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease
Nelson, A. R., Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.016 · Cited by 559
Roles for nigrostriatal—not just mesocorticolimbic—dopamine in reward and addiction
Wise, R. A. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.004 · Cited by 500
Shults, C. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509567103 · Cited by 476
Gender differences in Parkinson's disease: Clinical characteristics and cognition
Miller, I. N., & Cronin‐Golomb, A. (2010) · Movement Disorders · doi:10.1002/mds.23388 · Cited by 405 · cited 1×
“binding than males at the time of symptom onset and a more benign preclinical phase of PD, possibly due to protective effects exerted by estrogen [27, 28].”
BackgroundCellular adhesion molecules and atherogenesis
Price, D. T., & Loscalzo, J. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00153-9 · Cited by 388
Role of cytokines in inflammatory process in Parkinson’s disease
Sawada, M., Imamura, K., & Nagatsu, T. (2006) · Parkinson’s Disease and Related Disorders · doi:10.1007/978-3-211-45295-0_57 · Cited by 331 · cited 1×
“Furthermore, we identified gray matter atrophy throughout much of the cortex, including in anatomical locations that typically appear to be particularly sensitive to the effects of inflammation, such as the cerebellum, bilateral posterior cingulate gyrus, left parahippocampus, and left temporal gyrus [30].”
BackgroundBennett, R. E., Robbins, A. B., Hu, M., Cao, X., Betensky, R. A., Clark, T., Das, S., & Hyman, B. T. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710329115 · Cited by 299
Ward, A. M., Schultz, A. P., Huijbers, W., Van Dijk, K. R. A., Hedden, T., & Sperling, R. A. (2014) · Human Brain Mapping · doi:10.1002/hbm.22234 · Cited by 274
Identification of blood microRNAs associated to Parkinsońs disease
Margis, R., Margis, R., & Rieder, C. R. M. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.01.023 · Cited by 263
Stolp, H. B., & Dziegielewska, K. M. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.01005.x · Cited by 257
Shioya, M., Obayashi, S., Tabunoki, H., Arima, K., Saito, Y., Ishida, T., & Satoh, J. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01076.x · Cited by 245
Greenwood, J., Heasman, S. J., Alvarez, J. I., Prat, A., Lyck, R., & Engelhardt, B. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01140.x · Cited by 240
Vascular Degeneration in Parkinson's Disease
Guan, J., Pavlovic, D., Dalkie, N., Waldvogel, H. J., O'Carroll, S. J., Green, C. R., & Nicholson, L. F. B. (2013) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00628.x · Cited by 191
Longitudinal patterns of leukoaraiosis and brain atrophy in symptomatic small vessel disease
Lambert, C., Benjamin, P., Zeestraten, E., Lawrence, A. J., Barrick, T. R., & Markus, H. S. (2016) · Brain · doi:10.1093/brain/aww009 · Cited by 174
Rossi, B., Angiari, S., Zenaro, E., Budui, S. L., & Constantin, G. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0710432 · Cited by 172
González-Redondo, R., García-García, D., Clavero, P., Gasca-Salas, C., García-Eulate, R., Zubieta, J. L., Arbizu, J., Obeso, J. A., & Rodríguez-Oroz, M. C. (2014) · Brain · doi:10.1093/brain/awu159 · Cited by 162
Caminiti, S. P., Presotto, L., Baroncini, D., Garibotto, V., Moresco, R. M., Gianolli, L., Volonté, M. A., Antonini, A., & Perani, D. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.03.011 · Cited by 151
Brain-specific knockdown of miR-29 results in neuronal cell death and ataxia in mice
Roshan, R., Shridhar, S., Sarangdhar, M. A., Banik, A., Chawla, M., Garg, M., Singh, V. P., & Pillai, B. (2014) · RNA · doi:10.1261/rna.044008.113 · Cited by 150
Increased CSF biomarkers of angiogenesis in Parkinson disease
Janelidze, S., Lindqvist, D., Francardo, V., Hall, S., Zetterberg, H., Blennow, K., Adler, C. H., Beach, T. G., Serrano, G. E., van Westen, D., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002151 · Cited by 150
Vascular parkinsonism—characteristics, pathogenesis and treatment
Korczyn, A. D. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.61 · Cited by 149
Impaired Cerebrovascular Hemodynamics are Associated with Cerebral White Matter Damage
Purkayastha, S., Fadar, O., Mehregan, A., Salat, D. H., Moscufo, N., Meier, D. S., Guttmann, C. R., Fisher, N. D., Lipsitz, L. A., & Sorond, F. A. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.180 · Cited by 148
MicroRNA-29a Is a Candidate Biomarker for Alzheimer’s Disease in Cell-Free Cerebrospinal Fluid
Müller, M., Jäkel, L., Bruinsma, I. B., Claassen, J. A., Kuiperij, H. B., & Verbeek, M. M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9156-8 · Cited by 146
Pattern of Regional Cortical Thinning Associated with Cognitive Deterioration in Parkinson’s Disease
Pagonabarraga, J., Corcuera-Solano, I., Vives-Gilabert, Y., Llebaria, G., García-Sánchez, C., Pascual-Sedano, B., Delfino, M., Kulisevsky, J., & Gómez-Ansón, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054980 · Cited by 138
Neuroanatomical substrate of visuospatial and visuoperceptual impairment in Parkinson's disease
Pereira, J. B., Junqué, C., Martí, M., Ramirez‐Ruiz, B., Bargalló, N., & Tolosa, E. (2009) · Movement Disorders · doi:10.1002/mds.22560 · Cited by 136
Theory of mind in Parkinson's disease and related basal ganglia disorders: A systematic review
Bodden, M. E., Dodel, R., & Kalbe, E. (2010) · Movement Disorders · doi:10.1002/mds.22818 · Cited by 127
Monahan, A. J., Warren, M., & Carvey, P. M. (2008) · Cell Transplantation · doi:10.3727/096368908784423328 · Cited by 125
Overexpression of blood microRNAs 103a, 30b, and 29a in l -dopa–treated patients with PD
Serafin, A., Foco, L., Zanigni, S., Blankenburg, H., Picard, A., Zanon, A., Giannini, G., Pichler, I., Facheris, M. F., Cortelli, P., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001258 · Cited by 122
Voxel‐wise meta‐analysis of gray matter abnormalities in idiopathic Parkinson’s disease
Pan, P., Song, W., & Shang, H. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03474.x · Cited by 120
Salience network and parahippocampal dopamine dysfunction in memory‐impaired Parkinson disease
Christopher, L., Duff‐Canning, S., Koshimori, Y., Segura, B., Boileau, I., Chen, R., Lang, A. E., Houle, S., Rusjan, P., & Strafella, A. P. (2015) · Annals of Neurology · doi:10.1002/ana.24323 · Cited by 108
Jellema, R. K., Passos, V. L., Zwanenburg, A., Ophelders, D. R. M. G., Munter, S. D., Vanderlocht, J., Germeraad, W. T. V., Kuypers, E., Collins, J. J. P., Cleutjens, J. P. M., et al. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-13 · Cited by 102
Tarawneh, R., Head, D., Allison, S., Buckles, V., Fagan, A. M., Ladenson, J. H., Morris, J. C., & Holtzman, D. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0202 · Cited by 96
Swirski, M., Miners, J. S., de Silva, R., Lashley, T., Ling, H., Holton, J., Revesz, T., & Love, S. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0077-y · Cited by 96
Haarmann, A., Nowak, E., Deiß, A., van der Pol, S., Monoranu, C.-M., Kooij, G., Müller, N., van der Valk, P., Stoll, G., de Vries, H. E., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1417-0 · Cited by 90
White matter alterations in Parkinson’s disease with normal cognition precede grey matter atrophy
Rektor, I., Svátková, A., Vojtíšek, Ľ., Zikmundová, I., Vaníček, J., Király, A., & Szabó, N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0187939 · Cited by 87
Adhesion Molecules, Altered Vasoreactivity, and Brain Atrophy in Type 2 Diabetes
Novak, V., Zhao, P., Manor, B., Sejdić, E., Alsop, D., Abduljalil, A., Roberson, P. K., Munshi, M., & Novak, P. (2011) · Diabetes Care · doi:10.2337/dc11-0969 · Cited by 85
Huang, C.-W., Tsai, M.-H., Chen, N.-C., Chen, W.-H., Lu, Y.-T., Lui, C.-C., Chang, Y.-T., Chang, W.-N., Chang, A. Y. W., & Chang, C.-C. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0938 · Cited by 82
Self-citationCorticolimbic gray matter loss in Parkinson’s disease without dementia
Nishio, Y., Hirayama, K., Takeda, A., Hosokai, Y., Ishioka, T., Suzuki, K., Itoyama, Y., Takahashi, S., & Mori, E. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02980.x · Cited by 73
Temporal lobe changes in early, untreated Parkinson's disease
Martin, W. R. W., Wieler, M., Gee, M., & Camicioli, R. (2009) · Movement Disorders · doi:10.1002/mds.22680 · Cited by 72
Xu, Y., Yang, J., Hu, X., & Shang, H. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8122-3 · Cited by 71
Al-Bachari, S., Vidyasagar, R., Emsley, H. C., & Parkes, L. M. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16688919 · Cited by 70
Ji, K., Eu, M. Y., Kang, S., Gwag, B. J., Jou, I., & Joe, E. (2008) · Glia · doi:10.1002/glia.20677 · Cited by 69
Wang, J., Wang, Y., Wang, Y., Ma, Y., Lan, Y., & Yang, X. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.444463 · Cited by 64
Tchalla, A. E., Wellenius, G. A., Travison, T. G., Gagnon, M. M., Iloputaife, I., DANTOINE, T. F., Sorond, F. A., & Lipsitz, L. A. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05180 · Cited by 63
MiR-29a modulates the angiogenic properties of human endothelial cells
Yang, Z., Wu, L., Zhu, X., Xu, J., Jin, R., Li, G., & Wu, F. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.054 · Cited by 57
Gray matter atrophy associated with mild cognitive impairment in Parkinson’s disease
Chen, F.-X., Kang, D., Chen, F., Liu, Y., Wu, G., Li, X., Yu, L., Lin, Y., & Lin, Z. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.12.055 · Cited by 57
Emerging roles of epigenetic mechanisms in Parkinson’s disease
Habibi, E., Masoudi‐Nejad, A., Abdolmaleky, H. M., & Haggarty, S. J. (2011) · Functional & Integrative Genomics · doi:10.1007/s10142-011-0246-z · Cited by 55
Micro RNA ‐22 regulates inflammation and angiogenesis via targeting VE ‐cadherin
Gu, W., Zhan, H., Zhou, X., Yao, L., Yan, M., Chen, A., Liu, J., Ren, X., Zhang, X., Liu, J., et al. (2017) · FEBS Letters · doi:10.1002/1873-3468.12565 · Cited by 55
Allavena, R., Noy, S., Andrews, M., & Pullen, N. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090437 · Cited by 53
Systemic inflammation and alterations to cerebral blood flow in obstructive sleep apnea
Chen, H.-L., Lin, H., Lu, C., Chen, P., Huang, C., Chou, K., Su, M., Friedman, M., Chen, Y., & Lin, W. (2017) · Journal of Sleep Research · doi:10.1111/jsr.12553 · Cited by 52
Self-citationPlasma VCAM1 levels correlate with disease severity in Parkinson’s disease
Perner, C., Perner, F., Gaur, N., Zimmermann, S., Witte, O. W., Heidel, F. H., Grosskreutz, J., & Prell, T. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1482-8 · Cited by 49 · cited 1×
“The elevation of cell adhesion molecules is an indicator of BBB integrity [15] and is related to disease severity in PD [16, 17] and white matter disintegrity in AD dementia [18].”
BackgroundAli, S. F., BINIENDA, Z. K., & Imam, S. Z. (2011) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph8124702 · Cited by 46
Haas, S. J.-P., Zhou, X., Machado, V., Wree, A., Krieglstein, K., & Spittau, B. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00007 · Cited by 44
Blood vessels and Parkinsonism
Barcia, C. (2004) · Frontiers in Bioscience · doi:10.2741/1145 · Cited by 41 · cited 1×
“BBB dysfunction may also be associated with angiogenesis [59].”
BackgroundChen, Y., Chen, H.-L., Lu, C., Chen, M., Chou, K., Tsai, N., Yu, C.-C., Chiang, P., & Lin, W. (2018) · European Radiology · doi:10.1007/s00330-018-5855-7 · Cited by 39
Self-citationChen, C.-C. V., Chen, Y.-C., Hsiao, H.-Y., Chang, C., & Chern, Y. (2013) · Journal of Biomedical Science · doi:10.1186/1423-0127-20-47 · Cited by 32
Self-citationLin, W.-C., Chen, P.-C., Huang, Y., Tsai, N., Chen, H.-L., Wang, H., Lin, T., Chou, K., Chen, M., Chen, Y.-W., et al. (2016) · Medicine · doi:10.1097/md.0000000000002206 · Cited by 30
Self-citationLee, S.-Y., Chen, M., Chiang, P., Chen, H.-L., Chou, K., Chen, Y.-C., Yu, C.-C., Tsai, N., Li, S.-H., Lu, C.-H., et al. (2018) · BMC Neurology · doi:10.1186/s12883-018-1074-8 · Cited by 27
Self-citationChiang, P., Chen, H.-L., Lu, C., Chen, Y., Chou, K., Hsu, T., Chen, M., Tsai, N., Li, S.-H., & Lin, W.-C. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1317-z · Cited by 26
Self-citationBrain mediators of systemic oxidative stress on perceptual impairments in Parkinson’s disease
Lin, W., Chou, K., Lee, P., Huang, Y., Tsai, N., Chen, H.-L., Cheng, K., Wang, H., Lin, T., Li, S.-H., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0749-9 · Cited by 21
Self-citationLiu, C., Zhong, Q., & Huang, Y. (2017) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.241.183 · Cited by 19
Lin, W.-C., Chen, H.-L., Hsu, T., Hsu, C., Huang, Y., Tsai, N., & Lu, C. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00323 · Cited by 18
Self-citationPrice, C. F., Burgess, D. J., & Kastellorizios, M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.065 · Cited by 17
Research works printed but not linked: 1
- Sobhani A. Ebrahimi H. Ebrahimi A. VCAM-1 as a endothelial factor for diagnosis of dementia in Parkinson’s disease Joural of Neurology and Neuroscience 2018 9 1 p. 243
Cited by
Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms
Huang, X., Hussain, B., & Chang, J. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13569 · Cited by 709
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E.-K., & Pettersson, S. (2021) · Brain · doi:10.1093/brain/awab156 · Cited by 281
Blood-Brain Barrier Dysfunction in CNS Disorders and Putative Therapeutic Targets: An Overview
Archie, S. R., Al Shoyaib, A., & Cucullo, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111779 · Cited by 220
Chen, T., Dai, Y., Hu, C., Lin, Z., Wang, S., Yang, J., Zeng, L., Li, S., & Li, W. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00557-1 · Cited by 189
Self-citationAsaoka, D., Xiao, J., Takeda, T., Yanagisawa, N., Yamazaki, T., Matsubara, Y., Sugiyama, H., Endo, N., Higa, M., Kasanuki, K., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220148 · Cited by 156
Metadata
- Authors
- Yu, C.-C., Chen, H.-L., Chen, M.-H., Lu, C.-H., Tsai, N.-W., Huang, C.-C., Chang, Y.-Y., Li, S.-H., Chen, Y.-S., Chiang, P.-L., & Lin, W.-C.
- Affiliations
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Corresponding author
- Lin, Wei-Che
- ORCID
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2020-07-14
- Volume
- 2020
- Pages
- 1-12
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- PMC
- PMC7376437
- OpenAlex
- W3043199888
- Cited by
- 37
- References
- 84
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 7 · 2021: 7 · 2020: 1
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Oxidative Medicine and Cellular Longevity (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Chang Gung Memorial Hospital (CMRPG8E0621, CMRPG8C0021, CMRPG890801, CMRPG8B0831, CMRPG891511, 104-2314-B-182A-053, 103-2314-B-182A-010-MY3)
- National Science Council (CMRPG8E0621, CMRPG8C0021, CMRPG890801, CMRPG8B0831, CMRPG891511, 104-2314-B-182A-053, 103-2314-B-182A-010-MY3)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- Parkinson's disease, vascular inflammation, gray matter atrophy, VCAM-1, microRNA, miR-22, miR-29a, blood-brain barrier dysfunction, neurovascular unit, disease severity, peripheral inflammation, neuroinflammation, brain volume changes
- MeSH terms
- Atrophy, Brain, Female, Humans, Inflammation, Male, Middle Aged, Parkinson Disease, Risk Factors, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.